Drug Trial Radar · NCT05714202
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,135
Actual
Start
Mar 23, 2023
Primary completion
Sep 18, 2029
Study completion Sep 18, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Conditions
- Bladder Cancer
Interventions
TAR-200Drug
TAR-200 will be administered intravesically.
CetrelimabBiological
Cetrelimab will be administered.
BCG VesicultureBiological
BCG will be administered intravesically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS)Time frame: Up to 5 years 2 months
Locations
240 sites in 21 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Arkansas Urology
Little Rock, Arkansas
VA Long Beach Health Care System
Long Beach, California
Genesis Research, LLC - West Coast Urology
Los Alamitos, California
Cedars Sinai Medical Center
Los Angeles, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Genesis Research
San Diego, California
Providence Saint Johns Cancer Institute
Santa Monica, California
Providence Medical Foundation
Santa Rosa, California
Colorado Clinical Research
Lakewood, Colorado
Urological Research Network
Hialeah, Florida
Orlando Health Cancer Institute
Orlando, Florida
Sarasota Memorial Hospital
Sarasota, Florida
Grady Memorial Hospital
Atlanta, Georgia
The Emory Clinic Department of Urology
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Duly Health and Care
Lisle, Illinois
Blessing Hospital
Quincy, Illinois
Urology of Indiana
Carmel, Indiana
First Urology
Jeffersonville, Indiana
AMR Kansas City Oncology
Merriam, Kansas
Wichita Urology Group
Wichita, Kansas
Chesapeake Urology Research Associates
Hanover, Maryland
Lahey Hospital & Medical Center
Burlington, Massachusetts
University of Michigan
Ann Arbor, Michigan
University Of Minnesota
Minneapolis, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota
The Urology Center, PC
Omaha, Nebraska
Cooper Health System MD Anderson Cancer Center at Cooper
Camden, New Jersey
VA NY Harbor Healthcare System
New York, New York
Icahn School of Medicine at Mt. Sinai
New York, New York
Associated Medical Professionals of Ny
Syracuse, New York
SUNY Upstate Med Univ
Syracuse, New York
Vidant Urology - Greenville
Greenville, North Carolina
Cleveland Clinic
Cleveland, Ohio
Central Ohio Urology Group
Gahanna, Ohio
Centers for Advanced Urology LLC d b a MidLantic Urology
Bala-Cynwyd, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
UPMC Shadyside Hospital
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.